Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema

Keyphrases

• Intravitreous 100%
• Diabetic Macular Edema 100%
• Vascular Endothelial Growth Factor 100%
• Plasma Vascular Endothelial Growth Factor 100%
• Growth Factor Concentration 100%
• Anti-vascular Endothelial Growth Factor Therapy 100%
• Bevacizumab 81%
• Ranibizumab 81%
• Aflibercept 72%
• Factor Level 63%
• Plasma Samples 18%
• Treatment Group 18%
• Retreatment 9%
• Change of Measure 9%
• Comparative Effectiveness Trial 9%
• Heart Stroke 9%
• Confidence Interval 9%
• Enzyme-linked Immunosorbent Assay (ELISA) 9%
• Group Differences 9%
• 3-group 9%
• Treatment Algorithm 9%
• Systemic Side Effects 9%
• Heart Attack 9%
• Treatment Difference 9%
• Systemic Factors 9%
• Baseline-free 9%
• Anti-vascular Endothelial Growth Factor (anti-VEGF) 9%
• Concentration Factor 9%
• N-251 9%
• Plasma Collection 9%
• Difference in Mean 9%
• Return to Normal 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Vasculotropin 100%
• Diabetic Macular Edema 100%
• Endothelial Cell Growth Factor 100%
• Bevacizumab 69%
• Ranibizumab 69%
• Aflibercept 61%
• Enzyme-Linked Immunosorbent Assay 7%
• Heart Infarction 7%
• Cerebrovascular Accident 7%
• Side Effect 7%
• Vasculotropin A 7%

Neuroscience

• Vascular Endothelial Growth Factor 100%
• Endothelial Cell Growth Factor 100%
• Blood Plasma 100%
• Bevacizumab 69%
• Ranibizumab 69%
• Aflibercept 61%
• Vasculotropin A 7%
• Cerebrovascular Accident 7%
• Myocardial Infarction 7%